Loading
A phase 3 trial of Linvoseltamab, Daratumumab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) is a phase 3 interventional study registered as NCT07393282 by Regeneron Pharmaceuticals, with 270 participants planned, started 2026-05-21 and due to reach its primary completion in 2033-07-27. Interventions recorded: Linvoseltamab, Daratumumab. Conditions listed: High Risk Smoldering Multiple Myeloma (HR-SMM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Linvoseltamab, Smouldering multiple myeloma, Regeneron, T-cell engagers (bispecific).
Shares Linvoseltamab, Smouldering multiple myeloma, Regeneron, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Monoclonal antibodies.
Shares Smouldering multiple myeloma, Daratumumab, Monoclonal antibodies, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/